🔔Notification of Selection: Oral Presentation at TIBCS 2026🔔
| 2026 Taipei International Breast Cancer Symposium Oral Presentation | |||
|---|---|---|---|
| 📍 Room 701A, Taipei Nangang Exhibition Center, Hall 2 |
📅 Sat., September 19, 2026 | ||
| Time | # | Topic | Presenter |
| 10:30-10:40 | 1 | CDH1-Loss Driven Unfolded Protein Response (UPR) Suppression and Transcriptomic-Proteomic Discordance in mTOR-AKT Axis Define Therapeutic Vulnerabilities in Invasive Lobular Carcinoma | Wen-Ying Lin |
| 10:40-10:50 | 2 | Pre-treatment tumor microenvironment profiling identifies resting mast cells as a predictor of resistance to neoadjuvant pembrolizumab-based therapy in triple-negative breast cancer | Chi-Cheng Huang |
| 10:50-11:00 | 3 | Proportion of Endocrine Insensitivity After CDK4/6 Inhibitors Across Endocrine Therapy Based Regimens: A Secondary Analysis Using Reconstructed Individual Patient Data | Shang-Hsuan Peng |
| 11:00-11:10 | 4 | Impact of Undertreatment on Survival in Elderly Breast Cancer: A Nationwide Population-Based Cohort | Jun-Hee Lee |
| 11:10-11:20 | 5 | Comparative Genomic Profiling of Circulating Tumor DNA and Tissue DNA Reveals Complementary Genomic Information in Japanese Patients with Metastatic Breast Cancer | Yuri Fujimoto |
| 11:20-11:30 | 6 | PG2-Associated Immune Priming Enhances Checkpoint Inhibitor Activity: Integrated Clinical Absolute Lymphocyte Count Dynamics and Preclinical Validation in Breast Cancer Models | Ming-Shen Dai |
| 11:30-11:40 | 7 | Residual ductal carcinoma in situ and axillary nodal disease after neoadjuvant chemotherapy: a subtype-specific analysis in human epidermal growth factor receptor 2-positive and triple-negative breast cancer | Chihoon Lee |
| 11:40-11:50 | 8 | Clinicopathologic characteristics of Asian American breast cancer patients by ethnic and geographic subgroup: A 12-year single-institution experience | Andrew Seto |
| 11:50-12:00 | 9 | Carry-Over Effect of Immune Checkpoint Inhibitors on Overall Survival in Patients with Advanced Cancers: A Systematic Review and Meta-Regression Analysis | Shang-Hsuan Peng |
| 12:00-12:10 | 10 | Validation of the ASTRRA-derived Composite Risk Model for Ovarian Function Suppression Benefit in Premenopausal HR-Positive Breast Cancer | Dahn Byun |
| 12:10-13:10 | - | 🍱 Lunch Time | |
| 13:10-13:20 | 11 | False Estradiol Elevation During Abemaciclib Therapy: Clinical and Ex Vivo Evidence of Platform-Specific Immunoassay Interference | Hsing-Wu Chen |
| 13:20-13:30 | 12 | SGLT2 inhibitors and risk of distant metastasis in breast cancer patients with type 2 diabetes: a target trial emulation with biological plausibility analysis | Cho-Hao Lee |
| 13:30-13:40 | 13 | SHMT2 Couples One-Carbon Metabolism to Redox Homeostasis to Drive Triple Negative Breast Cancer (TNBC) Metastasis | Yen-Dun Tzeng |
| 13:40-13:50 | 14 | Trends of Breast Cancer Incidence, and Mortality by County-Level Income Disparities from 2000 to 2021 | Min Kyoon Kim |
| 13:50-14:00 | 15 | Sole Intraoperative Radiotherapy (IORT) versus External Beam Radiotherapy (EBRT) for Early-Stage Breast Cancer: A Nationwide Cohort Study Using the Taiwan National Health Insurance Research Database | Yu-Chen Hsu |
| 14:00-14:10 | 16 | Pharmacogenomic Repurposing of Cardiac Glycosides Against the ATP Synthasome in Metastatic Breast Cancer | Chia-Jung Li |
| 14:10-14:20 | 17 | Next Generation Estrogen Receptor Degraders in Patients with Estrogen Receptor Positive (ER+), Human Epidermal Growth Factor Receptor 2-negative (HER2-) Metastatic Breast Cancer with Endocrine Resistance: A Systematic Review, and Meta-Analysis | Tzu-Tung Kan |
| 14:20-14:30 | 18 | A propensity score-adjusted real-world comparison of CDK4/6 inhibitors in hormone receptor-positive, HER2-negative metastatic breast cancer: A Taiwanese multicenter cohort study | Tsung-Han Wu |
| 14:30-14:40 | 19 | Characteristics of the Tumor Immune Microenvironment in Residual Triple-Negative Breast Cancer After Neoadjuvant Therapy | Yumiko Akita |
| 14:40-15:00 | - | ☕ Coffee Break | |
| 15:00-15:10 | 20 | Revisiting adjuvant chemotherapy in premenopausal hormone receptor-positive, human epidermal growth factor receptor 2-negative early breast cancer: real-world evidence from an Asian cohort | Jen-Yu Chuang |
| 15:10-15:20 | 21 | Minnelide Reprograms Multidrug-Resistant Breast Cancer Through the miR-6838-5p/CARMA3/Ferroptosis Defense Axis | Tung-Wei Hsu |
| 15:20-15:30 | 22 | Real-world efficacy and safety of TS-1 plus endocrine therapy in hormone receptor-positive, HER2-negative early-stage breast cancer: A multicenter Taiwanese experience including NATALEE-eligible population. | Ching-Ting Wei |
| 15:30-15:40 | 23 | ILCness unmasks hidden lobular-like states within ductal breast cancer | Masanori Oshi |
| 15:40-15:50 | 24 | Luteolin-7-O-glucoside suppresses hormone receptor-positive breast cancer progression and metastasis through the K63-linked polyubiquitinated USP7-H3K56ac-PLK1 axis | Joseph Lin |
| 15:50-16:00 | 25 | Current Status of Breast Reconstruction After Mastectomy and the Risk of Postoperative Complications by Timing of Reconstruction: A Nationwide Population-Based Cohort Study in Korea | So-Youn Jung |